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The Pathogenic A2V Mutant Exhibits Distinct Aggregation Kinetics, 
Metal Site Structure, and Metal Exchange of the Cu2+-Aβ Complex 
Arun K. Somavarapu, Fei Shen, Kaare Teilum, Jingdong Zhang, Susanne Mossin, Peter W. Thulstrup, 
Morten J. Bjerrum, Manish K. Tiwari, Daniel Szunyogh, Peter M. Søtofte, Kasper P. Kepp* and Lars 
Hemmingsen*
Abstract: A prominent current hypothesis is that impaired metal 
ion homeostasis may contribute to Alzheimer’s Disease (AD). We 
elucidate the interaction of Cu2+ with wild-type (WT) Aβ1-40 and 
the genetic variants A2T and A2V which display increasing 
pathogenicity as A2T<WT<A2V. Cu2+ significantly extends the lag 
phase in aggregation kinetics, in particular for the pathogenic A2V 
variant. Additionally, a rapid, initial, low intensity ThT response is 
observed, possibly reflecting formation of Cu2+ induced 
amorphous aggregates, as supported by AFM and CD 
spectroscopy, again most notably for the A2V variant. EPR 
spectroscopy gives pKa values for transition between two 
Cu2+ coordination geometries (component I and II) of 7.4 (A2T), 
7.9 (WT), and 8.4 (A2V), i.e. component I is stabilized at 
physiological pH in the order A2T<WT<A2V. Similarly, 1H-NMR 
relaxation exhibits the same trend for the non-coordinating 
aromatic residues (A2T<WT<A2V), and implies markedly faster 
inter-peptide Cu2+exchange for the A2V variant than for WT and 
A2T. We therefore hypothesize that component I of the Cu-Aβ 
complex is related to pathogenicity, accounting for both the 
pathogenic nature of the A2V variant and the protective nature of 
the A2T variant.    
 
More than 30 million people world-wide suffer from Alzheimer's 
Disease (AD);[1,2] a neurodegenerative disorder that involves loss 
of cognitive skills and life quality.[3] The biochemical causes of AD 
remain obscure, current treatments are symptomatic and delay 
disease progression by only a few months, and more effective 
treatments of AD thus remain highly prioritized.[4,5] AD is 
associated with major extracellular plaque deposits and 
intracellular neurofibrillar tangles.[6] The senile plaques consist of 
partly modified (N-truncated, oxidized and metal-bound) β-
amyloid (Aβ) peptides organized as regular β-sheet-structured 
fibrils.[7–9] The three major genetic risk factors of familial AD, 
mutations in the genes APP, PSEN1, and PSEN2 are all related 
to Aβ strongly implying a role of Aβ in AD, viz. the amyloid 
hypothesis of AD.[7,9,10]  
The broad clinical spectrum of AD[6,11], the facts that >95% of 
patients do not have a genetic predisposition directly related to 
A, and that age is the main risk factor of the disease,[12] strongly 
imply that amyloids are not pathogenic in themselves, but that an 
age-dependent event must cause the disease.[13] Identifying non-
amyloid features that trigger A-driven disease is the motivation 
of the present work. Specifically, metal ion binding[14–16] and 
oxidative modifications[17] are characteristic of AD and enforced in 
the aging human brain,[12,18] and particularly in the hippocampus 
where AD initiates. [19,20] The upregulation of metal transport 
proteins in APP/PSEN1 mutant expressing mice[21] and of some 
metallothioneins[22], and metal-enrichment in senile 
plaques[15,23,24], suggest that age-enforced metal interactions 
define the pathogenicity of A.[14,15] 
15 sequence variants naturally occurring in humans have been 
identified in the Aβ1-42 region of APP (672−713). Of these, the A2T 
and A2V mutations are of particular interest, because the A2T 
variant is protective against cognitive decline in elderly,[25] 
whereas the A2V variant is pathogenic in homozygous 
individuals.[26] The first 16 amino acids comprise a high-affinity 
Cu2+ binding site of Aβ.[14,24,27,28], and the carbonyl oxygen or 
deprotonated backbone amide nitrogen at position 2 have been 
proposed to be part of the first coordination sphere,[23,24,29] making 
the A2T and A2V variants particularly interesting in the context of 
the effect of metal ions in AD. In this work we investigate the 
binding of Cu2+ to A, and the effect on aggregation and structure 
for three A variants WT, A2V, and A2T. 
 
 
Figure 1. Aggregation kinetics monitored by ThT fluorescence of 20 μM Aβ1-40 
WT, A2T, and A2V, with A)  0 μM Cu2+, B)  10 μM Cu2+, C)  20 μM Cu2+, and 
D)−F) are expansions of the first 10 hours time trace of A) – C). All samples 
were in 43 mM hepes pH 7.4, 86 mM NaCl, 9 µM edta, 12 µM ThT, 37 ºC, and 
shaking was applied prior to each fluorescence reading. Note that the Cu2+ 
available for binding by A was controlled using edta, that is, this “free” Cu2+ is 
the excess concentration of Cu2+ over edta as indicated. 
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Aggregation kinetics of all three variants (WT, A2T, and A2V) 
was elucidated by Thioflavin T (ThT) fluorescence spectroscopy 
(Figure 1, S1-S5, and Tables S1-S4). In this experiment series we 
used edta for a dual purpose: 1) In the absence of added Cu2+ to 
bind trace amounts of metal ions, and 2) to control the 
concentration of free Cu2+: With 9 µM edta and 0, 10, and 20 µM 
Cu2+ in the three series (Figure 1A-C), thus effectively having 0, 
1, and 11 µM (or 0, 0.05 and 0.55 eq. with respect to Aβ) free 
Cu2+. In itself edta does not appear to affect the aggregation 
kinetics (Figure S6). In the absence of Cu2+ only minor differences 
in the lag time are observed for the three variants, and 
qualitatively, the expected concentration dependence of the lag 
time and final ThT fluorescence is observed (Figure 1A, S1 and 
S5). Day to day and batch to batch variations are presented in 
Figures S7-S8, indicating that these observations are 
reproducible. Similar results have previously been obtained[30-33], 
although with some controversy concerning the order of the lag 
times for the three variants. We show that there is a batch to batch 
variation of this order, see Figure S9. Upon addition of Cu2+ the 
lag phase is extended for all three variants in agreement with 
literature[34–36] (Figure 1, A-C). Most interestingly, the A2V variant 
is particularly susceptible to the presence of Cu2+, and exhibits a 
much extended lag phase as compared to the WT and the A2T 
variant. This may be pathogenically relevant, as the oligomers 
formed prior to fibrillation are believed to be the pathogenic 
species[37-39]. Moreover, Cu2+ addition gives rise to a rapid low-
intensity ThT response, most prominent for the A2V variant 
(Figure 1F). CD spectroscopic and AFM data, vide infra, imply that 
this early weak ThT response reflects formation of large 
amorphous aggregates with no well-defined secondary structure, 
or a spectrum of species with differing secondary structure. Even 
very low free Cu2+ concentration (1 µM free Cu2+ / 20 µM A, 
Figure 1B) significantly increases tlag, and does so particularly for 
the A2V variant. Thus, with as little as 0.05 eq. Cu2+, all the 
peptides are affected by the presence of Cu2+. Accordingly, a 
simple model based on the high affinity of Aβ for Cu2+,[40] where 
Cu2+ binds to 5% of the peptides and leaves the remaining 95% 
unaffected, is not in agreement with the data.  
This conclusion is supported by the paramagnetic relaxation 
enhancement (PRE) recorded in 1H-NMR, where all peptides are 
affected by the presence of 0.1 eq. Cu2+ within a very short time 
span, vide infra. These findings agree with the sub-stoichiometric 
early Cu2+-induced non-fibrillar aggregation observed for the wild-
type Aβ by Pedersen et al.[41] Higher free Cu2+ concentrations, yet 
still at sub-stoichiometric conditions (11 µM free Cu2+ / 20 µM A, 
Figure 1C) further delays the fibrillation. All the observed trends 
of the ThT experiments for the A2T, WT, and A2V variants of Aβ 
are qualitatively maintained at low ionic strength (Figure S3), and 
when no shaking is applied (Figure S4), i.e. these conclusions are 
robust against such changes in experimental conditions. 
AFM data (Figure 2 A-C, Figure S10 A-C) recorded for samples 
that were dropcasted on mica sheets and dried for 4 hours, 
display no significant indication of aggregation as compared to the 
background (Figure S13). This observation corroborates the ThT 
fluorescence data, indicating no significant aggregation at early 
times in the absence of Cu2+, and is further supported by the CD 
spectroscopic data (Figure 3A), indicating no significant presence 
of ordered secondary structure, vide infra. After two weeks fibrils 
appear for both the WT and A2T variant, while the A2V variant 
has assembled into aggregates with no clear presence of fibrils 
(Figure 2G-I, Figure S11 A-C). After three weeks (Figure 2 M-O, 
Figure S12 A-C), the WT and A2T variant remain fibrillary (Figure 
2M and 2N), and while the A2V variant exhibits clear fibril-like 
structures, the morphology and length differ significantly from the 
other two variants (Figure 2O, Figure S12C). The fibrils are 
considerably longer, the height distribution significantly shifted 
towards larger values, and there appear to be “beads” deposited 
along the fibrils, possibly reflecting amorphous aggregates 
associating with the fibrils. Addition of Cu2+, controlling the free 
Cu2+ concentration using edta in the same manner as in the ThT 
fluorescence, vide supra, gives rise to formation of large 
aggregates for all three variants (Figure 2 D-F, J-L, P-R) already 
after 4 hours, and overall these large aggregates persist for the 
duration of the experiment series. The results are in agreement 
with literature data for the WT.[42] 
 
 
Figure 2. AFM images (5 × 5 µm2, tapping mode) of Aβ1-40 variants at different metal:peptide ratios (0:1 or 0.55:1) and 20 μM A, 4 mM hepes pH 7.4, 9 μM edta 
and 37°C, without shaking, and with sample age as indicated. A-C) sample age of ~ 4 hours; D-F) same as A-C in presence of 20 μM Cu2+; G-I) sample age of 2 
weeks; J-L) same as G-I in presence of 20 μM Cu2+; M-O)  sample age of 3 weeks; P-R) same as M-O in presence of 20 μM Cu2+. Corresponding height distributions 
are presented in Figures S10-S12. 
CD spectroscopic data indicate that initially (Figure 3A) all three 
variants display signatures of random coil in agreement  with 
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literature,[30,42] and although there are minor changes upon 
addition of Cu2+, no obvious formation of ordered secondary 
structure occurs at short time scales (Figure 3C). 
Figure 3B and 3D display CD spectra recorded for the end point 
samples of the ThT time trace (Figure S3, Table S3) without and 
with Cu2+ present, respectively. In the absence of Cu2+ the spectra 
are very similar for WT and A2T, while the A2V variant gives a 
distinct signal. This is intriguing since all three samples have 
reached essentially the same final level of ThT response (Figure 
S3C). The difference cannot originate simply from differences in 
the concentration of Aβ because the absorption spectra exhibit 
only minor differences (Figure S14). This indicates that the 
secondary structure composition of fibrils of A2V differs from that 
of the other two variants. 
 
 
Figure 3. CD spectra recorded immediately after sample preparation, panels A 
and C, and for end point samples, panels B and D, collected from ThT 
experiments (Figure S3; note that A2V + Cu2+ (panel D) had not formed ThT 
responsive fibrils at the end point). 20 μM A, 4 mM hepes pH 7.4, 0 µM Cu2+ 
(panels A and B) or 20 μM Cu2+ (panels C and D), 9 μM edta and 37 °C. 
 
The CD spectra are typical for antiparallel β-sheet structure. 
However, these features are clearly reduced for the A2V variant, 
possibly due to signal cancellation from contributions by less 
ordered species (Table S5), in agreement with the distinct 
morphological properties as probed by AFM. Thus, the CD and 
AFM data indicate that the A2V variant forms more complex 
aggregates, encompassing both fibrillar structures and 
components richer in helix or coil structure, even when the 
fibrillation has converged towards the final ThT fluorescence. In 
the presence of Cu2+, interestingly, the A2V variant still displays 
no well-defined secondary structure after 90 hours in the Cu2+-
induced prolonged lag phase (Figure 3D). This implies that the 
A2V peptides are trapped in Cu2+-induced aggregates with no 
well-defined or a spectrum of secondary structures prior to 
fibrillation. The WT and A2T variant have fibrillized (Figure S3D) 
and display very similar CD spectra indicating well-defined 
secondary structure (Figure 3D), similar to spectra observed for 
the WT after eight days by Kirkitadze et al., which were interpreted 
as indicating increased α-helix character.[43] Based on 
deconvolution of the CD data, the change induced by Cu2+ 
corresponds to a ~10% lower content of antiparallel -sheet and 
an increase in both helix and random coil (~6-7%) content (Table 
S5). 
Paramagnetic relaxation enhancement (R1,PRE) for the aromatic 
region of the 1H-NMR spectrum for all three Aβ1-16 variants is 
shown in Figure 4A (for 1H-NMR spectra see Figure S15). The 
observed PRE of the His6, His13, and His14 residues is higher 
than for the others, reflecting that they are involved in copper 
coordination in the WT,[23,28] and that this is also the case for the 
two genetic variants. The PRE for WT and A2T are similar, while 
for A2V it is significantly higher. The experiments are carried out 
with only 0.1 eq. Cu2+ relative to the peptide, i.e. the rapid 
relaxation of protons of all the peptides indicates that Cu2+ is 
rapidly exchanged between peptides. To test if this might occur 
via free Cu2+ and be due to weaker Cu2+ binding of the A2V variant, 
potentiometric and fluorometric determination of the Kd for metal 
ion dissociation was conducted, see Figures S16-S18, Table S6. 
The results demonstrate only minor (less than a factor of ~3) 
differences in the Kd values between the A2T, WT, and A2V 
variants, and therefore the affinity of the peptides for Cu2+ is too 
high for the exchange to occur via free Cu2+.[44] Thus, the PRE 
experiments reflect Cu2+ exchange occurring via transient 
formation of metal ion bridged dimers or higher oligomers, and 
this process is apparently significantly faster for the A2V variant 
than for the WT and A2T variant.  
 
 
Figure 4. A) Paramagnetic relaxation enhancement (R1,PRE) for the aromatic 
residues in A1-16.  300 μM A, 30 μM CuCl2, 60 μM glycine, 150 mM of NaCl, 
~10% D2O and pH 7.4 at 25 C, no buffer. B) EPR spectra obtained at 77 K for 
300 M A in the presence of 240 M CuCl2, 10 mM hepes and 110 mM NaCl 
at pH 7.5, 8.0, and 8.5.  
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EPR spectra recorded for all three Aβ1-16 variants (Figure 4B) 
reveal the coexistence of two Cu2+ coordination geometries. The 
spin Hamiltonian parameters for component I are g = 2.258, g = 
2.05, A = 17710-4 cm-1 and for component II g = 2.230, g = 2.05, 
A = 15710-4 cm-1 in agreement with literature.[29,45] Despite the 
fact that the mutations (A2T and A2V) occur near the metal site 
binding region of the peptide, the parameters of the two sites do 
not change between variants, but the population differs and 
depends on pH.  The pKa values for the transition from component 
I to component II is ~7.4 (A2T), ~7.9 (WT), and ~8.4 (A2V) (Figure 
S19). Importantly, this feature reflects the trend in clinical 
pathogenicity (A2T<WT<A2V). While it was shown previously that 
component I dominates in A2V[45] at physiological pH, this finding 
becomes more significant in the light of the opposite effect of the 
protective A2T variant. That is, component I is stabilized as 
A2T<WT<A2V at physiological pH. Interestingly, the 1H-NMR 
relaxation rates observed for the Phe4 and Tyr10 protons (Figure 
4A) exhibit the same trend (A2T<WT<A2V), suggesting that Cu2+ 
exchange between peptides may occur via component I or a 
transient structure more readily accessible from component I than 
from component II. The relative relaxation rates of the His 
(imidazole) protons show a slightly different pattern 
(A2T≈WT<A2V), possibly due to a slightly different propensity to 
coordinate to Cu2+.  
Using peptides of increasing clinical pathogenicity (A2T < WT 
< A2V) we have demonstrated that Cu2+ binding site structure and 
exchange, differs between the variants in a manner that parallels 
the pathogenicity. We tentatively propose that component I which 
is stabilized in the A2V variant at physiological pH, is related to 
pathogenicity. It is conceivable that the preponderance of 
component I is also the origin of the initial weak ThT response and 
the delayed fibrillation, observed for the A2V variant in the 
presence of Cu2+. It is interesting to note that this is in excellent 
agreement with the increased propensity of the WT Aβ-Cu2+ 
complex to rapidly form aggregates under mildly acidic conditions, 
where component I is also stabilized.[46] This would imply that the 
WT protein should exhibit a longer lag time than the A2T variant 
in the presence of Cu2+, which cannot be concluded unequivocally 
from the current study. However, other minor differences between 
WT and the A2T variant aggregation kinetics rate constants might 
counteract the effect of component I, giving rise to the observed 
time course of the ThT fluorescence. 
Although this work represents only pure in vitro chemistry, it is 
tempting to speculate on the implications for the presumably far 
more complex molecular speciation occurring during the 
development of Alzheimer’s disease. The correlation between 
properties of the Aβ-Cu2+ complex and pathology of the A2V 
variant, supports a role of Cu2+ in the etiology of AD, and points 
to component I as a potential molecular culprit. Remarkably, if this 
hypothesis is correct, it presents a common age-enforced 
molecular mechanism for the initiation of both sporadic and 
genetic AD, suggesting a synergistic effect between genetic and 
chemical effectors in the development of AD, intertwining the 
etiology of familial (A2V) and sporadic (WT) AD with a central role 
of Cu2+ in both forms of the disease. 
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